Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva/Barr let the competition continue

Executive Summary

Teva will divest assets in 29 U.S. markets to settle Federal Trade Commission charges that the generic giant's $8.9 billion acquisition of rival firm Barr would be anticompetitive. The consent order requires Teva and Barr to sell assets of certain formulations of 16 overlapping on-market generic drugs, representing approximately $60 million in the companies' annual sales, and 13 overlapping pipeline generic drugs; drugs include those commonly used to treat acid reflux disease, cancer, bacterial infections, diabetes and depression. Assets will be divided between current generic competitors Watson and Qualitest
Advertisement

Related Content

Teva Is Eager to Expand in Specialty Pharma
Advertisement
UsernamePublicRestriction

Register

PS050485

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel